1
|
Troupis CJ, Berman JS, Hammerschlag G, Upton AJ, Rhodes AN. Incidental central pulmonary emboli in outpatients with deep vein thrombosis. Intern Med J 2024; 54:626-631. [PMID: 37872855 DOI: 10.1111/imj.16249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 09/05/2023] [Indexed: 10/25/2023]
Abstract
BACKGROUND While it has been demonstrated that large asymptomatic pulmonary embolism (PE) can occur, many studies have assessed inpatients or patients with known risk factors for venous thromboembolism (such as malignancy). There are few data regarding incidental PE in outpatients with deep vein thrombosis (DVT) or assessing whether these emboli occur centrally or peripherally in the pulmonary arteries. AIMS To determine the rates of incidental central and peripheral PE in outpatients with proximal and distal DVT. METHODS This was a retrospective cross-sectional study of 120 patients attending our community imaging clinic between January 2015 and March 2020, with ultrasound-confirmed lower limb DVT, and subsequent computed tomography pulmonary angiogram (CTPA) within 24 h. Exclusion criteria were symptoms indicative of PE. Imaging reports were retrospectively reviewed to record the proximity of DVT and the location of any PE as either central (pulmonary trunk or main pulmonary arteries) or peripheral (lobar, segmental or subsegmental pulmonary arteries). RESULTS Incidental PE occurred in 71 patients (59.2%), with a rate of 77.5% in proximal and 50.0% in distal DVT. Sixteen patients had central PE (13.3% of all patients with DVT; 22.5% of all patients with PE). Two patients (both with proximal DVT) had PE in the pulmonary trunk. CONCLUSIONS Incidental PE occur frequently in outpatients with lower limb DVT, including the possibility of asymptomatic central emboli. Further studies with larger patient cohorts would be useful to assess the utility of baseline chest imaging in outpatients with DVT.
Collapse
Affiliation(s)
| | | | - Gary Hammerschlag
- Department of Respiratory Medicine & Sleep Disorders, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | | | - Alexander N Rhodes
- Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Bozas G, Jeffery N, Ramanujam-Venkatachala D, Avery G, Stephens A, Moss H, Palmer J, Elliott M, Maraveyas A. Prognostic assessment for patients with cancer and incidental pulmonary embolism. Thromb J 2018; 16:8. [PMID: 29445314 PMCID: PMC5802055 DOI: 10.1186/s12959-017-0157-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2017] [Accepted: 12/21/2017] [Indexed: 12/18/2022] Open
Abstract
Background An incidental/unsuspected diagnosis of pulmonary embolism (IPE) in cancer patients is a frequent occurrence. This single-institution analysis of uniformly managed patients investigates short and long-term outcomes and proposes a prognostic risk score, aiming to assist clinical decision-making. Methods Data from a prospectively recorded cohort of 234 consecutive cancer patients with IPE were analysed. Multivariate logistic regression and the Cox regression survival methods were used to identify factors with independent association with early (30-day, 3-month, 6-month) mortality and survival. Receiver operator characteristic analysis (ROC) was used to assess appropriate cut-offs for continuous variables and the fitness of prognostic scoring. Results 30-day, 3-month and 6-month mortality was 3.4% (n = 8), 15% (n = 35) and 31% (n = 72) respectively. Recurrence during anticoagulation occurred in 2.6% (n = 6) and major haemorrhage in 2.1% (n = 5) of the patients. A prognostic score incorporating performance status (0 vs 1–2 vs 3–4) and the presence of new or worsening symptoms, with and without the consideration of the presence of incurable malignancy, correlated with overall survival (p < .001 respectively) as well as early mortality (AUC = .821, p = .004 and AUC = .805, p = 0.006, respectively). Conclusion A simple prognostic score incorporating basic oncologic clinical assessment and self-reported symptomatology could reliably stratify the mortality risk of ambulant cancer patients and IPE. Trial registration Audit registration No. 2013.287, Hull and East Yorkshire Hospitals Trust, 29/11/2013. Electronic supplementary material The online version of this article (10.1186/s12959-017-0157-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- George Bozas
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Natalie Jeffery
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Deiva Ramanujam-Venkatachala
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Ged Avery
- 2Hull and East Yorkshire NHS Hospitals Trust, Radiology Department, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Andrew Stephens
- 2Hull and East Yorkshire NHS Hospitals Trust, Radiology Department, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Hilary Moss
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - June Palmer
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Mandi Elliott
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| | - Anthony Maraveyas
- 1Hull and East Yorkshire NHS Hospitals Trust, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK.,3Hull York Medical School, Academic Oncology, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ UK
| |
Collapse
|
3
|
van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, Jiménez D, Portillo AK, O'Connell C, Liebman HA, Shteinberg M, Adir Y, Tiseo M, Bersanelli M, Abdel-Razeq HN, Mansour AH, Donnelly OG, Radhakrishna G, Ramasamy S, Bozas G, Maraveyas A, Shinagare AB, Hatabu H, Nishino M, Huisman MV, Klok FA. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 2016; 14:105-13. [PMID: 26469193 PMCID: PMC7480998 DOI: 10.1111/jth.13172] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 09/30/2015] [Indexed: 12/17/2022]
Abstract
UNLABELLED ESSENTIALS: We performed a pooled analysis of 926 patients with cancer-associated incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a higher risk of major hemorrhage. Recurrence risk is comparable after subsegmental and more proximally localized IPE. Our results support low molecular weight heparins over VKA and similar management of subsegmental IPE. BACKGROUND Incidental pulmonary embolism (IPE) is defined as pulmonary embolism (PE) diagnosed on computed tomography scanning not performed for suspected PE. IPE has been estimated to occur in 3.1% of all cancer patients and is a growing challenge for clinicians and patients. Nevertheless, knowledge about the treatment and prognosis of cancer-associated IPE is scarce. We aimed to provide the best available evidence on IPE management. METHODS Incidence rates of symptomatic recurrent venous thromboembolism (VTE), major hemorrhage, and mortality during 6-month follow-up were pooled using individual patient data from studies identified by a systematic literature search. Subgroup analyses based on cancer stage, thrombus localization, and management were performed. RESULTS In 926 cancer patients with IPE from 11 cohorts, weighted pooled 6-month risks of recurrent VTE, major hemorrhage and mortality were 5.8% (95% confidence interval [CI] 3.7-8.3%), 4.7% (95% CI 3.0-6.8%), and 37% (95% CI 28-47%). VTE recurrence risk was comparable under low molecular weight heparins (LMWH) and vitamin K antagonists (VKAs) (6.2% vs. 6.4%; hazard ratio [HR] 0.9; 95% CI 0.3-3.1), while 12% in untreated patients (HR 2.6; 95% CI 0.91-7.3). Risk of major hemorrhage was higher under VKAs than under LMWH (13% vs. 3.9%; HR 3.9; 95% CI 1.6-10). VTE recurrence risk was comparable in patients with an subsegmental IPE and those with a more proximally localized IPE (HR 1.1; 95% CI 0.50-2.4). CONCLUSION These results support the current recommendation to anticoagulate cancer-associated IPE with LMWH and argue against different management of subsegmental IPE.
Collapse
Affiliation(s)
- T van der Hulle
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - P L den Exter
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - B Planquette
- Department of Respiratory and Intensive Care Medicine, Hôpital Européen Georges-Pompidou, Université Paris Descartes, INSERM U 965, Paris, France
| | - G Meyer
- Department of Respiratory and Intensive Care Medicine, Hôpital Européen Georges-Pompidou, Université Paris Descartes, INSERM U 965, Paris, France
| | - S Soler
- Department of Internal Medicine, Hospital Sant Jaume, Olot, Gerona, Spain
| | - M Monreal
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | - D Jiménez
- Respiratory Department, Ramon y Cajal Hospital, IRYCIS and Alcala de Henares University, Madrid, Spain
| | - A K Portillo
- Respiratory Department, Ramon y Cajal Hospital, IRYCIS and Alcala de Henares University, Madrid, Spain
| | - C O'Connell
- Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - H A Liebman
- Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - M Shteinberg
- Pulmonology Institute, Faculty of Medicine, Carmel Medical Center, Technion, Israel Institute of Technology, Haifa, Israel
- CF Center, Faculty of Medicine, Carmel Medical Center, Technion, Israel Institute of Technology, Haifa, Israel
| | - Y Adir
- Pulmonology Institute, Faculty of Medicine, Carmel Medical Center, Technion, Israel Institute of Technology, Haifa, Israel
| | - M Tiseo
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - M Bersanelli
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - H N Abdel-Razeq
- Department of Internal Medicine and Department of Radiology, King Hussein Cancer Center, Amman, Jordan
| | - A H Mansour
- Department of Internal Medicine and Department of Radiology, King Hussein Cancer Center, Amman, Jordan
| | - O G Donnelly
- Leeds Institute of Cancer and Pathology, University of Leeds and St James' Institute of Oncology, Leeds, UK
| | | | - S Ramasamy
- St James' Institute of Oncology, Leeds, UK
| | - G Bozas
- Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK
| | - A Maraveyas
- Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, Cottingham, UK
| | - A B Shinagare
- Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
| | - H Hatabu
- Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
| | - M Nishino
- Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
| | - M V Huisman
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - F A Klok
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|